ThornhillJPBarkatiSWalmsleyS, et al. Monkeypox virus infection in humans across 16 countries—April-June 2022. N Engl J Med. 2022;387:679-691. doi:10.1056/NEJMoa2207323
2.
CurranKGEberlyKRussellOO, et al. HIV and sexually transmitted infections among persons with monkeypox cases—eight US jurisdictions, May 17-July 22, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1041-1047. doi:10.15585/mmwr.mm7136a1
3.
O’SheaJFilardoTDBamrah MorrisSWeiserJPetersenBBrooksJT. Interim guidance for prevention and treatment of monkeypox in persons with HIV infection—United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1023-1028. doi:10.15585/mmwr.mm7132e4
EronJJJrWilkinARamgopalM, et al. A daily single-tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically-suppressed adults living with HIV and end stage renal disease on chronic hemodialysis. Open Forum Infect Dis. 2020;7:S529-S530.
10.
TempestilliMD’AvolioADe NicoloAAgratiCAntinoriACicaliniS. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV. J Antimicrob Chemother. 2021;76:3320-3322. doi:10.1093/jac/dkab319
11.
PatonNIMusaaziJKityoC, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385:330-341. doi:10.1056/NEJMoa2101609
12.
ShafranSDHughesCA. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotype NRTI resistance [published online ahead of print August 16, 2022]. HIV Med. doi:10.1111/hiv.13376
13.
BirbeckGLFrenchJAPeruccaE, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia. 2012;53(1):207-214. doi:10.1111/j.1528-1167.2011.03335.x